

WEB TABLE I POST-DOSE SEROCONVERSION RATES AND GEOMETRIC MEAN TITRES (GMTs) RECORDED IN MMRV TRIALS

Reference	Age at first vaccination	Vaccine	Dose	Post-dose time point	N Immuno-genicity cohort	Seroconversion (%)				GMT (95% CI)			
						Measles	Mumps	Rubella	Varicella	Measles	Mumps	Rubella	Varicella
Knuf, <i>et al.</i> [13]	10-21 mo	MMRV	2	42-56 d	141*	99.3	100	100	100	4451 (3844-5155)	2298 (2064-2558)	93 (84-104)	3389 (2768-4148)
	10-21 mo	MMRV	2	42-56 d	142 [#]	98.6	99.3	100	100	4184 (3618-4838)	2195 (1968-2448)	106 (95-119)	2576 (2082-3187)
Schuster, <i>et al.</i> [14]	10-21 mo	MMRV	1	42 d	681	94.5	96.1	99.7	95.5	2584(2365-2825)	158(143-174)	63(59-67)	80(73-89)
		MMRV	2	42 d		98.3	99.4	99.7	99.7	3756(3473-4062)	589(543-640)	123(116-129)	1903(1716-2111)
		MMR+V	1	42 d	219	93.4	93.6	98.1	95.6	1645(1399-1935)	124(104-149)	83(73-94)	84(70-100)
		MMR	2	42 d		97.6	99.5	100	97.5	2176(1878-2521)	449(390-516)	136(124-148)	80(66-98)
Knuf, <i>et al.</i> [15]	12-18 mo	MMRV	2	42-56 d	311	100	98.0	100	100	6104(5640-6606)	1465(1344-1598)	102(95-109)	4932(4215-5771)
Knuf, <i>et al.</i> [16]				3 yr	225 [§]	98.5	97.4	100	99.4	3600(3135-4134)	1755(1549-1987)	52(46-59)	226(181-281)
		MMR+V	2	42-56 d	108	100	99.1	100	100	3719(3184-4345)	1668(1442-1929)	107(95-120)	155(126-190)
				3 yr	79 [§]	97.0	93.8	100	96.8	1819(1408-2350)	1455(1128-1875)	54(44-66)	106(60-188)
Halperin, <i>et al.</i> [17]	15-75 mo	MMRV	2	Pre-dose 2	189	96.3	97.4	100	96.2	1872(1604-2185)	1381(1205-1584)	86(75-97)	93(73-118)
				42 d		100	100	100	100	2375(2112-2672)	3941(3626-4283)	159(148-172)	2533(2140-2998)
		MMR+V	2	Pre-dose 2	189	96.8	91.4	99.5	99.5	2077(1785-2416)	1101(939-1291)	78(68-90)	97(80-120)
				42 d		99.5	99.5	100	100	2788(2471-3146)	3623(3268-4016)	162(150-175)	2555(2187-2985)
Gillet, <i>et al.</i> [18]	15-24 mo	MMRV	2	Pre-dose 2	88	87.5	92.0	96.6	-	1486(1090-2024)	927(957-1136)	93(75-114)	
				42 d		98.9	100	100	97.6	2428(1971-2992)	5663(4797-6684)	123(107-141)	93(72-121)
		V	2	42 d					100				1312(1048-1644)
		MMR+V	2	Pre-dose 2	97	97.9	95.7	100	-	2147(1774-2598)	1224(1009-1484)	105(90-122)	
				42 d		99.0	100	100	100	2677(2271-3154)	4763(4113-5516)	145(128-165)	144(119-174)
	2-6 years	V	2	42 d					100				1415(1163-1722)
		MMRV	2	Pre-dose 2	107	95.3	92.5	99.1	-	1812(1434-2289)	1349(1098-1656)	90(76-108)	
				42 d		100	100	100	97.9	2833(2396-3349)	6604(5702-7648)	166(149-185)	88(65-120)
		V	2	42 d					100				1110(886-1389)
		MMR+V	2	Pre-dose 2	100	97.0	92.0	98.0	-	2144(1750-2626)	1327(1063-1656)	73(60-88)	
				42 d		100	100	100	96.6	3011(2573-3523)	5167(4486-5952)	156(140-173)	88(67-114)
Lalwani, <i>et al.</i> [19]	9-15 mo	MMRV	1	Pre-dose 1	151	1.3	1.3	0.7	7.4				1145(917-1629)

Contd...

From pre-page...

Reference	Age at first vaccination	Vaccine	Dose	Post-dose time point	N Immuno-genicity cohort	Seroconversion (%)				GMT (95% CI)			
						Measles	Mumps	Rubella	Varicella	Measles	Mumps	Rubella	Varicella
			1	43 d		93.2	86.1	98.7	94.2	2014(1662-2439)	992(820-1200)	45(38-54)	121(91-160)
		MMRV	2	43 d		100	100	100	100	4471(3975-5029)	6428(5775-7155)	148(136-162)	5319(4319-6550)
		MMR	1	Pre-dose 1	156	1.9	1.9	2.6	8.3				
			1	43 d		88.2	84.2	99.3	2.8	1180(963-1447)	747(628-888)	64(56-73)	2.2(2.0-2.4)
		MMRV	2	43 d		100	100	100	98.6	3359(3018-3738)	10109(9224-11078)	165(152-179)	198(158-248)
		MMR	1	Pre-dose 1	75	2.7	2.7	1.7	2.7				
			1	43 d		87.5	83.3	100	1.4	1200(888-1622)	775(601-1000)	62(51-75)	2.2(1.8-2.6)
		MMR+V	2	43 d		100	100	100	95.8	2495(2064-3015)	4925(4201-5775)	173(153-196)	128(92-179)

*Intramuscular injection; #Subcutaneous injection; §Persistence cohort; GMT: geometric mean titres; MMR: trivalent measles, mumps and rubella vaccine; V: monovalent varicella vaccine; MMRV: quadrivalent measles, mumps, rubella and varicella vaccine.